<DOC>
	<DOCNO>NCT02092220</DOCNO>
	<brief_summary>This study test hypothesis wearable bionic pancreas system automatically deliver insulin glucagon provide superior regulation glycemia vs. usual care adult type 1 diabetes . Please note participant must work attend school one follow campus : Massachusetts General Hospital Boston , MA ; University Massachusetts Medical Center Worcester , MA ; University North Carolina Chapel Hill , NC ; Stanford University Palo Alto , CA .</brief_summary>
	<brief_title>A Multicenter Study Outpatient Automated Blood Glucose Control With Bihormonal Bionic Pancreas</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Age ≥18 year clinical type 1 diabetes least one year Diabetes manage use insulin pump ≥ 6 month Prescription medication regimen stable &gt; 1 month ( except medication affect safety study expect affect outcome study , judgement site principal investigator ) . Employee student work study week one participating campus ( Massachusetts General Hospital Boston , MA ; University Massachusetts Medical Center Worcester , MA ; University North Carolina Chapel Hill , NC ; Stanford University Palo Alto , CA ) Lives within 30 minute drivetime radius central monitoring location one study sit Willing remain within 60 minute drivetime radius central monitoring location one study sit 11day study arm Have someone 18 year age live , access sleep , willing house subject sleeping , willing receive call study staff check welfare study subject telemetry show technical problem severe biochemical hypoglycemia without subject response subject answer telephone ( two individual share role , must willing carefully coordinate subject one clearly designated responsibility give time ) Willing wear two infusion set CGM sensor change set frequently ( least one new glucagon infusion set daily ) Unable provide inform consent ( e.g . impaired cognition judgment ) Unable safely comply study procedure report requirement ( e.g . impairment vision dexterity prevents safe operation bionic pancreas , impaired memory , unable speak read English ) Current participation another diabetesrelated clinical trial , judgment principal investigator , compromise result study safety subject Pregnancy ( positive urine HCG ) , breast feeding , plan become pregnant immediate future , sexually active without use contraception Need go outside designate geographic boundary either arm study Current alcohol abuse ( intake average &gt; 3 drink daily last 30 day ) , use marijuana within 1 month enrollment , substance abuse ( use within last 6 month control substance marijuana without prescription ) Unwilling unable refrain drink 2 drink hour 4 drink day use marijuana trial Unwilling unable avoid use drug may dull sensorium , reduce sensitivity symptom hypoglycemia , hind decision make period participation study ( use beta blocker allow long dose stable subject meet criterion hypoglycemia unawareness take stable dose , use benzodiazepine narcotic , even prescription , may exclude accord judgment principal investigator ) History liver disease expect interfere antihypoglycemia action glucagon ( e.g . liver failure cirrhosis ) . Other liver disease ( i.e . active hepatitis , steatosis , active biliary disease , tumor liver , hemochromatosis , glycogen storage disease ) may exclude subject cause significant compromise liver function may unpredictable fashion . Renal failure dialysis Personal history cystic fibrosis , pancreatitis , pancreatic tumor , pancreatic disease besides type 1 diabetes Any known history coronary artery disease include , limited , history myocardial infarction , stress test showing ischemia , history angina , history intervention coronary artery bypass grafting , percutaneous coronary intervention , enzymatic lysis presume coronary occlusion ) Abnormal EKG consistent coronary artery disease increase risk malignant arrhythmia include , limited , evidence active ischemia , prior myocardial infarction , proximal LAD critical stenosis ( Wellen 's sign ) , prolong QT interval ( &gt; 440 m ) . Nonspecific ST segment T wave change ground exclusion absence symptom history heart disease . A reassuring evaluation cardiologist abnormal EKG finding may allow participation . Congestive heart failure ( establish history CHF , low extremity edema , paroxysmal nocturnal dyspnea , orthopnea ) History TIA stroke Seizure disorder , history nonhypoglycemic seizure within last two year , ongoing treatment anticonvulsant History hypoglycemic seizure coma last year History pheochromocytoma : fractionate metanephrines test patient history increase risk catecholamine secrete tumor : episodic treatment refractory ( require 4 medication achieve normotension ) hypertension paroxysms tachycardia , pallor , headache personal family history MEN 2A , MEN 2B , neurofibromatosis , von HippelLindau disease History adrenal disease tumor Hypertension systolic BP ≥160 mm Hg diastolic BP ≥100 despite treatment Untreated inadequately treat mental illness ( indicator would include symptoms psychosis , hallucination , mania , psychiatric hospitalization last year ) , treatment antipsychotic medication know affect glucose regulation . Electrically powered implant ( e.g . cochlear implant , neurostimulators ) might susceptible RF interference Unable completely avoid acetaminophen duration study History adverse reaction glucagon ( include allergy ) besides nausea vomit Established history allergy severe reaction adhesive tape must use study History eat disorder anorexia , bulimia , diabulemia omission insulin manipulate weight History intentional , inappropriate administration insulin lead severe hypoglycemia require treatment Use oral ( e.g . thiazolidinediones , biguanides , sulfonylurea , glitinides , DPP4 inhibitor , SGLT2 inhibitor ) antidiabetic medication Lives frequents area poor Verizon wireless network coverage ( would prevent remote monitor ) Any factor , opinion site principal investigator overall principal investigator , would interfere safe completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Bionic Pancreas</keyword>
	<keyword>Insulin</keyword>
	<keyword>Glucagon</keyword>
	<keyword>Continuous Glucose Monitor</keyword>
</DOC>